Scholarlink

Background <p>Individuals with Down syndrome (DS) develop a genetic form of Alzheimer’s disease (AD) due to an extra copy of chromosome 21, which contains the <i>APP</i> gene. Blood-based biomarkers of AD are becoming increasingly adopted in research and clinical practice. These tests hold promise for diagnosing AD in DS once validated.</p> Methods <p>In this exploratory study, we assessed plasma phospho-tau217 (p-tau217) in participants (n = 39) from the NIH Trial Ready Cohort – Down syndrome (TRC-DS), using predefined amyloid-PET cutoffs. Plasma p-tau217 was measured via two fully automated assays: C2N Diagnostics’ PrecivityAD2 mass spectrometry and Fujirebio’s Lumipulse immunoassay. The primary outcome was β-amyloid AD pathology, defined by amyloid PET &gt; 18 centiloids.</p> Results <p>Both p-tau217 assays showed high accuracy: AUCs of 0.94 (95% CI 0.84, 1.00) for Lumipulse and 0.91 (95% CI 0.77, 1.00) for C2N, with sensitivities of 0.88 (95% CI 0.62, 1.00), specificities of 0.90 (95% CI 0.77, 1.00) and 0.94 (95% CI 0.84, 1.00), and overall accuracies of 0.90 (95% CI 0.79, 0.97) and 0.92 (95% CI 0.82-1.00), respectively, when using maximized Youden index cutpoints.</p> Conclusion <p>These preliminary results are comparable to composite plasma measures. In summary, automated p-tau217 tests offer strong potential for routine AD screening in individuals with DS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploring automated plasma phospho-tau217 assays for the diagnosis of Down syndrome-related Alzheimer’s disease

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月2日

查看全文
  • Zinayida Schlachetzki,
  • Oliver Langford,
  • Matthew D. Zammit,
  • Michael C. Donohue,
  • Xiaoyu Zhou,
  • Sonal Sukreet,
  • Sara Abdel-Latif,
  • Joel B. Braunstein,
  • Robert A. Rissman,
  • Michael S. Rafii

摘要

Background

Individuals with Down syndrome (DS) develop a genetic form of Alzheimer’s disease (AD) due to an extra copy of chromosome 21, which contains the APP gene. Blood-based biomarkers of AD are becoming increasingly adopted in research and clinical practice. These tests hold promise for diagnosing AD in DS once validated.

Methods

In this exploratory study, we assessed plasma phospho-tau217 (p-tau217) in participants (n = 39) from the NIH Trial Ready Cohort – Down syndrome (TRC-DS), using predefined amyloid-PET cutoffs. Plasma p-tau217 was measured via two fully automated assays: C2N Diagnostics’ PrecivityAD2 mass spectrometry and Fujirebio’s Lumipulse immunoassay. The primary outcome was β-amyloid AD pathology, defined by amyloid PET > 18 centiloids.

Results

Both p-tau217 assays showed high accuracy: AUCs of 0.94 (95% CI 0.84, 1.00) for Lumipulse and 0.91 (95% CI 0.77, 1.00) for C2N, with sensitivities of 0.88 (95% CI 0.62, 1.00), specificities of 0.90 (95% CI 0.77, 1.00) and 0.94 (95% CI 0.84, 1.00), and overall accuracies of 0.90 (95% CI 0.79, 0.97) and 0.92 (95% CI 0.82-1.00), respectively, when using maximized Youden index cutpoints.

Conclusion

These preliminary results are comparable to composite plasma measures. In summary, automated p-tau217 tests offer strong potential for routine AD screening in individuals with DS.